

1  
2  
3  
4  
5  
6  
7  
8  
9  
10

**UNITED STATES DISTRICT COURT**  
**DISTRICT OF NEVADA**

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES OF AMERICA  
ex rel. CECILIA GUARDIOLA,

3:12-cv-00295-LRH-VPC

Plaintiff,

**ORDER**

v.

RENOWN HEALTH, et al.,

Defendants.

This order concerns the “data universe” for statistical sampling of claims in this case. At the June 8, 2015 case management conference (#127), the parties apprised the court of their dispute regarding the data universes for several claims. To resolve the matter, the court ordered relator to file a brief on the issue, to which defendants would respond and relator would reply. Relator filed her opening “memorandum” (#135) on July 27, 2015. Defendants filed a “response” (#138) on August 7, and relator replied (#142) on August 17. Relator’s brief indicates that only one universe remains a point of contention. Having considered the parties’ positions and other relevant papers, this order follows.

**I. BACKGROUND**

This is a qui tam action under the False Claims Act, 31 U.S.C. §§ 3729-33. Relator alleges that, while working at Renown from June 2006 through June 2014, she discovered the existence of a scheme whereby Renown knowingly submitted false inpatient reimbursement claims to Medicare that should have been billed on a less expensive, outpatient basis. Of relevance to this order is relator’s claim that Renown failed to address unreliable billing software in use at Renown, the Siemens billing system, by which Renown submitted fraudulent claims to Medicare.

To streamline this case, the parties will utilize statistical sampling. In June 2014, the parties filed briefs on the viability of statistical sampling. Over two days in August 2014, the

1 court held an evidentiary hearing at which statistical experts for both parties testified about  
2 statistical sampling. Relator’s expert, Dr. Constantin Yiannoutsos, explained that relator desired  
3 to extrapolate from a universe of claims data a statistically valid estimate of how many claims  
4 were improperly submitted for reimbursement to Medicare. (See #88 at 17-19.) By using  
5 statistical sampling, the parties are relieved from examining every single claim on an individual  
6 basis, a time-consuming and costly exercise. The adequacy and completeness of the underlying  
7 data universe necessarily determines the validity of his sampling plan. (See generally #75.)  
8 Following the hearing, the parties filed supplemental briefs.

9 In a November 5, 2014 order (#98), the court held that statistical sampling of claims was  
10 appropriate and would make this litigation more efficient and less costly. The court ordered that  
11 Renown produce certain data, including data for inpatient “zero-day stays.” (Id. at 6.) The court  
12 adopted relator’s proposed definition of a zero-day stay as one that was “less than 24 hours.” (Id.  
13 at 3.) The court’s order expressly observed that, as “[t]his case is in the discovery phase, . . . a  
14 ruling on admissibility or use of the statistical sampling will no doubt be debated later at the pre-  
15 trial stage of this case.” (Id.)

16 The instant dispute concerns the meaning of a zero-day stay and finalization of relator’s  
17 proposed sampling plan. In various papers and at the case management conferences, defendants  
18 repeatedly contended that, rather than expeditiously turning her attention to the task, relator has  
19 laboriously reviewed the produced data and compared it to “inadequate and over-inclusive data”  
20 from Noridian, the contracted Medicare claims processor in Nevada. (#125 at 16.) Because  
21 relator was surprised that there were fewer claims than she expected—which Renown contends  
22 lowers her chance of recovery and corresponding settlement pressure—Renown argues that she  
23 seeks at this late hour to acquire more data and alter the definition of a zero-day stay to include  
24 said data. (#138 at 5-6.)

25 Relator counters that Renown’s characterization is disingenuous because its production  
26 revealed a serious discrepancy in a portion of the data that complicates her statistical sampling.  
27 During the time period relevant to this case, Renown utilized two electronic billing systems:  
28 Siemens, and later Epic. (#135 at 6.) Siemens documented a patient’s “admit” time and

1 discharge time. Based upon those times, relator initially determined which claims constituted  
2 zero-day stays, based upon the adopted definition. However, relator later learned that the  
3 Siemens “admit” time was actually the patient’s registration time, i.e., the moment in which  
4 arrangements for the inpatient stay began. This is distinct from the patient’s admission time, i.e.,  
5 the moment at which the patient presents and begins receiving inpatient medical care. (Id. at 7.)  
6 As a result, an inpatient stay that Siemens documented as twenty-six hours in length, and thus  
7 would fall outside of a zero-day stay, may actually have lasted twenty-three hours, when  
8 measured from the actual admission time through discharge, and thus is a zero-day stay.

9 Because the Epic software accurately documents both the registration time and the  
10 admission time, Dr. Yiannoutsos determined through the Epic data that the median time  
11 difference between registration and admission is two hours for Emergency Room (“ER”)  
12 admissions, i.e., admissions that follow initial presentation in the ER, and 4.5 hours for non-ER  
13 admissions. (Id. at 7-9.) Thus, relator has informed Renown that she will include within her data  
14 universe for zero-day stays non-ER visits up to 28.5 hours in length, and ER visits up to twenty-  
15 six hours in length (hereinafter, the “time-adjusted claims”). She believes that the zero-day stay  
16 definition, as set in the court’s November order, is not so narrow that it turns on how Siemens  
17 documented the visit length. Instead, her position is that the zero-day stay definition measures the  
18 visit from the time care began—that is, admission—through discharge.

## 19 II. DISCUSSION

20 Before turning to the underlying dispute, the court observes that this issue presents in an  
21 odd procedural posture. Relator’s brief is styled as only a memorandum, and it states that she  
22 moves for nothing at all. As stated, she believes that the court’s prior order embraces her expert’s  
23 adjustment in methodology; thus, her position is that this issue is a sly attempt by Renown to  
24 achieve a premature evidentiary ruling through the discovery process.

25 In contrast, Renown argues that relator is attempting to revise the zero-day stay definition  
26 without first carrying the high burden for reconsideration. Unsurprisingly, Renown’s “response”  
27 to relator’s memorandum argues that reconsideration is unwarranted, largely on the basis of a  
28 challenge to Dr. Yiannoutsos’s conclusion regarding the time adjustments. The brief discusses

1 and disputes at some length his underlying factual premises and conclusions. Further, Renown  
2 argues that not only that inclusion of the time-adjusted claims in the sampling plan is unwarranted  
3 by the facts or law regarding inpatient admissions, but also will render relator’s sampling plan  
4 unreliable and confusing. Citing the court’s power to control discovery, Renown suggests that  
5 the court should embrace prevent the inclusion of these claims in the sampling plan.

6 This said, the briefs leave unaddressed a few pertinent questions. Relator does not state  
7 that Renown has denied any particular data requests that are necessary to her plan to include the  
8 time-adjusted claims; thus, it is unclear whether Renown need be ordered to produce the relevant  
9 data. Like relator, Renown does not move for any particular order, aside from urging the court to  
10 apply the reconsideration standard. Yet its “power-to-control-discovery” argument hints that it  
11 desires a ruling that would disallow the inclusion of these claims—a possible basis for Renown’s  
12 refusal to produce such data. If this inference is correct, Renown may seek sub silentio a  
13 protective order that would obviate its obligation to produce time-adjusted data. Notwithstanding  
14 these uncertainties, the court proceeds to rule on the matter.

15 **A. The time-adjusted data is discoverable. An order excluding the time-adjusted claims**  
16 **from the sampling plan would require an evidentiary ruling that is properly reserved**  
17 **for the District Court. Therefore, the court shall not exclude those claims from**  
18 **relator’s data universe.**

19 In its duty to aid the District Court in fair and speedy resolution of this case, this court  
20 supervises only discovery. The court begins with a pertinent inquiry: is the time-adjusted data  
21 discoverable?

22 “Parties may obtain discovery regarding any nonprivileged matter that is relevant to any  
23 party’s claim or defense . . . . Relevant information need not be admissible at the trial if the  
24 discovery appears reasonably calculated to lead to the discovery of admissible evidence.” Fed. R.  
25 Civ. P. 26(b). When weighing whether discovery is warranted, “[t]he question of relevancy  
26 should be construed liberally and with common sense and discovery should be allowed unless the  
27 information sought has no conceivable bearing on the case.” *Soto v. City of Concord*, 162 F.R.D.  
28 603, 610 (N.D. Cal. 1995). The court has broad discretion in determining whether evidence is  
relevant for discovery purposes, see *Survivor Media, Inc. v. Survivor Productions*, 406 F.3d 625,

1 635 (9th Cir. 2005), and it has similarly broad discretion to manage the discovery process, *Hunt v.*  
2 *County of Orange*, 672 F.3d 606, 616 (9th Cir. 2012).

3 The time-adjusted data is discoverable, for it is indisputably relevant. Evidence is relevant  
4 when “it has any tendency to make a fact more or less probable than it would be without the  
5 evidence” and “the fact is of consequence in determining the action.” Fed. R. Evid. 401. Relator  
6 has adequately explained the basis for her belief that the time-adjusted claims properly fall within  
7 the data universe for zero-day stays, based upon the guidelines for an inpatient stay<sup>1</sup> and the  
8 problem with the Siemens’ “admit time.” Within these claims, there may be additional instances  
9 of fraud that may be extrapolated to the entire universe, which similarly includes these time-  
10 adjusted claims. Ultimately, inclusion may render Dr. Yiannoutsos’s statistical sampling—and  
11 therefore, his expert testimony—more reliable and accurate at trial. Notably, one of relator’s  
12 claims in this case concerns the use of the Siemens software. Hence, it is apparent that the data is  
13 relevant and discoverable. Fed. R. Civ. P. 26(b). Even if the data (or testimony) is not ultimately  
14 admissible, it cannot be said at this stage that discovery of the time-adjusted data is (or was) not  
15 reasonably calculated to lead to admissible evidence.

16 Because the evidence is relevant, this court must permit its discovery. To the extent that  
17 questions of evidence arise in discovery, the court’s only role is to verify and grant discovery  
18 requests that are “reasonably calculated” to produce admissible evidence, see Fed. R. Civ. P.  
19 26(b), even if the parties disagree about ultimate admissibility. It is true that district courts serve  
20 as gatekeepers for expert testimony, as they alone must ensure that “any and all scientific  
21 testimony or evidence admitted is not only relevant, but reliable.” *Daubert v. Merrell Dow*  
22 *Pharm., Inc.*, 509 U.S. 579, 589 (1993). Yet “[w]hether Daubert’s specific factors are, or are not,  
23 reasonable measures of reliability in a particular case is a matter that the law grants the trial judge  
24 broad latitude to determine.” *Kumho Tire Co. v. Carmichael*, 526 U.S. 137, 153 (1999)  
25 (emphasis added). Implicit within this authority is an important limitation: so long as requested  
26 discovery is relevant under discovery’s broad standard, this court—supervising discovery as it

---

27  
28 <sup>1</sup> Here, relator cites the Medicare regulations and Noridian’s guidance. (See #142 at 7-8; #142-3.)

1 does—is not to employ the discovery rules to prematurely decide evidentiary issues that are  
2 reserved for the District Court or the jury.

3 For this reason, district courts within the Ninth Circuit have declined to prematurely  
4 adjudicate evidentiary issues related to expert testimony during the discovery process.  
5 “Questions concerning the accuracy and reliability of a witness’ factual basis, data and methods  
6 goes to the weight and credibility of the witness’ testimony and are questions of fact properly  
7 reserved for the jury.” *Urrutia v. Ek Dahl*, No. cv-031990-PHX-PGR, 2005 WL 5976564, at \*4  
8 (D. Ariz. July 15, 2005). “Unless beyond the realms of reason and reliability, [issues that speak  
9 to an expert’s methodology] are fully within the province of experts to debate and a jury to  
10 resolve.” *Apple iPod iTunes Antitrust Litig.*, No. 05-CV-0037-YGR, 2014 WL 4809288, at \*6  
11 (N.D. Cal. Sept. 26, 2014).

12 Renown’s argument, that the court must forbid inclusion of the time-adjusted data on  
13 discovery grounds, is entirely unpersuasive. In fact, its brief belies its position that this is a  
14 discovery issue at all. Renown vehemently disputes that inclusion of the time-adjusted data will  
15 produce a reliable sampling plan. Supported by its outside medical billing consultant, Christine  
16 Melnykovich, Renown vigorously contests the individual cases upon which Dr. Yiannoutsos  
17 relied when calculating the median time differences by delving into the particular facts of those  
18 cases. (See #138 at 14-16, 18-19; #138-10 at 4-5; #140.) This position is plainly a challenge to  
19 the reliability of Dr. Yiannoutsos’s methods. Necessarily encompassed within the ultimate  
20 determination as to the reliability of his methods, and therefore the admissibility of his testimony,  
21 may be inquiries into the facts of those cases, the proper definition of inpatient stays, and other  
22 related issues. None of those matters is properly before this court. Renown “retain[s] the right,  
23 and will have the opportunity, to question or attack the reliability of [Dr. Yiannoutsos and his  
24 methods] and any opinions and conclusions he bases thereon[.]” through motions in limine or at  
25 trial. *Arredondo v. Delano Farms Co.*, No. 1:09-CV-01247-MJS, 2014 WL 5106401, at \*10  
26 (E.D. Cal. Oct. 10, 2014).

27 In sum, the court finds that the data is relevant under the broad discovery standard. The  
28 court declines Renown’s invitation to prevent relator from including the time-adjusted claims in

1 her sampling plan because to do so during the discovery process would improperly and  
2 prematurely decide an evidentiary issue. Rule 26(b) compels the court to allow discovery and  
3 obligates Renown to produce the time-adjusted data if it has not already done so. Moreover, to  
4 the extent Renown’s brief can be construed as a motion for a protective order, it is denied in  
5 absence of a demonstration of good cause. See *Foltz v. State Farm Mut. Auto. Ins. Co.*, 331 F.3d  
6 1122, 1130 (9th Cir. 2003) (“A party asserting good cause bears the burden, for each particular  
7 document it seeks to protect, of showing that specific prejudice or harm will result if no protective  
8 order is granted.”).

9 **B. The zero-day stay definition encompasses the time-adjusted claims. To the extent  
10 reconsideration is necessary, the court finds that it is appropriate.**

11 The court next considers a second question: does the November order regarding statistical  
12 sampling (#98) permit the inclusion of the time-adjusted data in the sampling plan? Here, even if  
13 the data is discoverable, Renown seemingly suggests that relator has not been granted permission  
14 to include it under the terms of the November order. In reviewing the August 2014 hearing  
15 transcript and other papers, the court is persuaded that the meaning of a “zero-day stay,” one of  
16 “less than 24 hours,” contemplates a stay from the time of admission through discharge. At heart,  
17 the issue is not about individual number of hours in the stay, but instead how a “stay” is to be  
18 measured.

19 When Dr. Yiannoutsos testified as to the boundaries of the data universe that he and  
20 relator envisioned, he defined a zero-day stay as “a hospital stay of less than 24 hours,” which he  
21 described with reference to the “time of admission.” (#88 at 28:17-24; see also *id.* at 40:2-23  
22 (describing the zero-day stays in terms of provision of care, rather than registration time).)  
23 Defense counsel also spoke of the zero-day claims in reference to time of admission, rather than  
24 time of registration. (*Id.* at 182:9-13.) On the second day of the hearing, relator’s counsel asked  
25 relator for her exact definition of a zero-day stay, and she stated: “[a] patient is admitted or  
26 discharged on the same day . . . or is in the hospital less than 24 hours.” (#88 at 291:11-16.)<sup>2</sup>

---

27  
28 <sup>2</sup> The court observes that relator’s statement is somewhat ambiguous, referencing as it does 24  
hours “in the hospital,” which could be read as encompassing registration or other waiting time

1 When the court adopted relator’s proposed definition (#98 at 3; see also #88 Exh. 2), it adopted  
2 the definition as she and Dr. Yiannoutsos explained it—namely, a stay of less than twenty-four  
3 hours measured from admission to discharge.

4           Consequently, the November order permits inclusion of the time-adjusted claims.  
5 Relator’s explanation of the time-adjusted claim evinces that the adjustment aims to respect this  
6 definition while accounting for the Siemens software’s complication of the data by its misleading  
7 “admit” time. Renown’s suggestion that relator is attempting to dramatically expand the data  
8 universe, in light of the facts and foregoing discussion, is entirely meritless. Instead, relator is  
9 simply making a minor adjustment to her sampling plan in response to newly discovered facts  
10 about the Siemens data. Renown invites the court to burden relator with the responsibility for her  
11 lack of knowledge about the data one year ago. The court declines that invitation. There is no  
12 legitimate dispute that relator’s adjustments aim to capture stays of less than twenty-four hours.  
13 Therefore, her time adjustments fall within scope of the November order’s definition.

14           Because relator is acting within the terms of the prior order, she need not move for  
15 reconsideration. Had she done so, the court would have granted the motion it in light of the  
16 circumstances. “‘A motion for reconsideration is an ‘extraordinary remedy, to be used sparingly  
17 in the interests of finality and conservation of judicial resources.’” *Peterson v. Miranda*, 57 F.  
18 Supp. 3d 1271, 1275 (D. Nev. 2014) (quoting *Kona Enters., Inc. v. Estate of Bishop*, 229 F.3d  
19 877, 890 (9th Cir. 2000)). The court may reconsider a prior order where the court is presented  
20 with newly discovered evidence, an intervening change of controlling law, manifest injustice, or  
21 where the prior order was clearly erroneous. Fed. R. Civ. P. 59(e); *Peterson*, 57 F. Supp. 3d at  
22 1275. “Further, a district court ‘possesses the inherent procedural power to reconsider, rescind, or  
23 modify an interlocutory order’ for sufficient cause.” *Peterson*, 57 F. Supp. 3d at 1275 (quoting  
24 *City of Los Angeles, Harbor div. v. Santa Monica Baykeeper*, 254 F.3d 882, 887 (9th Cir. 2001)).

---

25  
26  
27 before care begins. However, the other zero-day stay discussions at the hearing resolve the  
28 ambiguity, for they consistently contemplated the stay as measured from the time of care. The  
court declines to read relator’s words as in conflict with those of her expert.



1 The circumstances satisfy this standard. First, newly-discovered evidence arose. What  
2 relator once reasonably understood as the admission times—the Siemens “admit” times—is  
3 actually the time of registration. The fact has obvious impact upon the zero-day stay definition  
4 when read narrowly. Second, it would be manifestly unjust to shackle relator to a narrow reading  
5 of order given the factual developments. To do so would require her to have knowledge about the  
6 data before it had been produced. Finally, the court’s inherent powers permit it to modify the  
7 prior order for “sufficient cause,” and there is little doubt that these circumstances are sufficient.

8 Accordingly, the court advises the parties that the definition of a “zero-day stay” for the  
9 purpose of relator’s sampling may include stays of less than twenty-four hours, measured from  
10 the time inpatient care began through the time of discharge. The definition provided in docket 98  
11 shall be construed by the parties to include the time-adjusted claims. Again, the court  
12 acknowledges that Renown disagrees with the propriety of relator’s time-adjustments, and it may  
13 raise and argue that point as one of evidence at the appropriate moment.

### 14 III. CONCLUSION

15 For the foregoing reasons, relator may include the Siemens time-adjusted claims in her  
16 data universe. If it has not already done so, Renown **SHALL EXPEDITIOUSLY PRODUCE**  
17 data consistent with relator’s proposal to include the time-adjusted claims. Relator **SHALL**  
18 **EXPEDITIOUSLY FINALIZE** her statistical sampling plan upon Renown’s production of any  
19 outstanding data.

20 The parties are directed to **MEET AND CONFER** and determine a plan by which they  
21 will comply with the requirements of this order. By **Friday, September 11**, the parties **SHALL**  
22 **FILE** a joint status report regarding production of the time-adjusted data, if necessary, and the  
23 date by which relator’s sampling plan will be finalized.

24  
25 **IT IS SO ORDERED.**

26 **DATED:** September 1, 2015.

27   
28 **UNITED STATES MAGISTRATE JUDGE**